// startup autopsy
Stellar Biotechnologies
A marine biotech pioneer that couldn't survive its own clinical sea change
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: Stellar spent over a decade refining its KLH platform without securing a major pharmaceutical partnership or achieving clinical proof of concept in a lead indication.
Key Events Timeline
FOUNDING
Stellar Biotechnologies founded in California to commercialize KLH-based proteins for immunotherapy applications.
PRODUCT LAUNCH
Company advances KLH conjugate platform into early-stage collaborative research agreements with pharma partners.
FUNDING
Final funding round raised, totaling approximately $17.57M, as company struggles to attract new institutional investors.
SHUTDOWN
Stellar Biotechnologies ceases operations after failing to secure partnerships or regulatory approvals needed to commercialize its platform.